Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MDH1 | P40925 | 1/20 | 0.54 |
| ▸ | MDH2 | P40926 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059647 | 0.93 | SMN1; SMN2 (0.55) | NPC1RAB9ATP53MEN1GAA | |
| SCHEMBL5060108 | 0.90 | RAB9A (0.64) | NPC1RAB9ATP53MEN1GAA | |
| SCHEMBL5066333 | 0.90 | RAB9A (0.64) | NPC1RAB9ATP53MEN1GAA | |
| SCHEMBL5061335 | 0.86 | CYP3A4 (0.66) | NPC1RAB9ATP53MEN1GAA | |
| SCHEMBL5059273 | 0.84 | CYP3A4 (0.69) | RAB9AMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL5059586 | 0.84 | CYP3A4 (0.69) | RAB9AMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL5055835 | 0.84 | NPC1 (0.47) | NPC1RAB9ATP53MEN1GAA | |
| SCHEMBL5059536 | 0.83 | SMN1; SMN2 (0.58) | HPGDALDH1A1SMN1; SMN2MAPTMDH1 | |
| SCHEMBL5056244 | 0.83 | KMT2A (0.67) | MEN1GAAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5059716 | 0.82 | CYP3A4 (0.66) | RAB9AMEN1KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | NPC1 970/4885RAB9A 3844/4885TP53 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.